Weekly docetaxel in pretreated metastatic breast cancer patients: A phase I-II study

Cecilia Nisticò, Francesco Cognetti, Luciano Frontini, Sandro Barni, Gianluigi Ferretti, Emilio Bria, Michele Milella, Carlo Garufi, Federica Cuppone, Barbara Vanni, Paolo Carlini, Edmondo Terzoli

Research output: Contribution to journalArticle


Objective: We conducted a phase I-II study to determine the maximum tolerated dose (MTD), toxicity and activity of weekly docetaxel administration in pretreated metastatic breast cancer patients. Methods: In phase I, cohorts of 3 women with pretreated metastatic breast cancer were treated with a 1-hour infusion of docetaxel at 30, 35, 40 mg/m2/week after premedication with two doses of dexamethazone 8 mg 12 h apart. Subsequently, a cohort of 28 women was treated at the MTD for 24 consecutive weeks in a phase II setting and was assessed for toxicity and activity. Results: Three patients were treated at each of the first two dose levels; 9 patients were treated at the 3rd level (40 mg/m2/week). Dose-limiting toxicities (DLTs) were experienced at that level by 2/6 patients of the first two accrued groups and in 2/3 patients of the 3rd (confirmation) group, thus establishing the subsequent phase II dose at 35 mg/m2/week. Two out of 28 evaluable patients (7.1%, 95% CI 0-16.7) showed complete responses, whereas 8 (28.6%, 95% CI 11.8-45.3) showed partial responses, and an objective response rate of 35.7% (95% confidence interval, CI 18-53.5%). In addition, 8 patients (28.6%) had stable disease. The median time to progression and overall survival were 5 (range 1-15) and 15 months (95% CI 7-23), respectively. One patient experienced 1 episode of grade 3 neutropenia. Severe asthenia was the main reason for interruption of chemotherapy (10 patients, 35.5%). Conclusions: In pretreated metastatic breast cancer patients, the sustained weekly administration of docetaxel, even though it demonstrated an activity similar to a 3-weekly schedule could not be maintained for the planned 24 weeks due to the progressive emergence of nonhematological side effects that approached DLTs.

Original languageEnglish
Pages (from-to)356-363
Number of pages8
Issue number4-6
Publication statusPublished - Aug 2005



  • Docetaxel
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nisticò, C., Cognetti, F., Frontini, L., Barni, S., Ferretti, G., Bria, E., Milella, M., Garufi, C., Cuppone, F., Vanni, B., Carlini, P., & Terzoli, E. (2005). Weekly docetaxel in pretreated metastatic breast cancer patients: A phase I-II study. Oncology, 68(4-6), 356-363. https://doi.org/10.1159/000086975